Trial Profile
Rifaximin for Preventing Acute Graft Versus Host Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Graft-versus-host disease
- Focus Biomarker; Therapeutic Use
- 06 Sep 2009 New trial record